what glp 1 is covered by insurance How many adults with private health could use GLP-1 drugs How Employers Can Manage GLP-1

Glucagon-Like Peptide 1 Receptor Agonists and the Eye AT A GLANCE Glucagon-like peptide 1 receptor agonists (GLP-1RA) are FDA-approved for treating type 2 diabetes and are commonly used in weight loss regimens

Other potential causes include: Certain medications, including GLP-1 receptor agonists, opioid pain medications, and some antidepressants Previous stomach or abdominal surgery that affects nerves involved in digestion Neurological conditions such as Parkinson's disease or multiple sclerosis Viral infections that temporarily disrupt nerve function Autoimmune disorders that damage nerves or muscles involved in digestion Connective tissue diseases such as scleroderma In some cases, doctors can't identify a specific cause

Data from clinical trials show A1C reductions of 12% when combining these agents, though individual responses vary based on baseline insulin secretion capacity, beta-cell function, and genetic factors influencing GLP-1R expression

The group included people 18 to 64 with a body mass index (BMI) of 25 or over, which indicates overweight or obesity

References Su N, Yang J, Xie Y, et al

8 Considerations to reduce the risk of emesis for patients taking GLP-1 or GLP-1/GIP receptor agonist medications would include avoiding or limiting emetogenic agents